Fc Engineered Anti-Human IL23 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ14] (CAT#: BioBet-C014ZP) Datasheet

Target
IL23
Isotype
Whole Humanized Antibody
Description
CDC-enhanced Tildrakizumabis a Fc-modified anti-IL23 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Tildrakizumab, the Fc region of Tildrakizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Moderate-severe plaque psoriasis
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Tildrakizumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL23A
Full Name
interleukin 23 subunit alpha
Background
This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells.
Alternative Names
P19; SGRF; IL-23; IL-23A; IL23P19
Gene ID
UniProt ID
Trade name
Ilumya
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB14004
CAS number
1326244-10-3
Antibody Isotype
Humanized IgG1
Description
Tildrakizumab is a humanized IgG1κ antibody designed to treat monoclonal antibodies against immune-mediated inflammatory diseases. The US Food and Drug Administration (FDA) approved Tildrakizumab for the treatment of moderate to severe plaque psoriasis in 2018.
Indication
Moderate-severe plaque psoriasis
Synonyms
tildrakizumab-asmn
UNII
DEW6X41BEK

IL-23 is a naturally occurring cytokine involved in inflammation and immune responses. Studies have shown that targeting IL-23p19 alone is a promising method for treating patients with moderate to severe chronic plaque psoriasis.
Tildrakizumab is a humanized IgG1κ antibody used to block interleukin-23. The drug selectively binds to the IL-23 p19 subunit and neutralizes its function. IL-23 regulates Th17 cells and is a potent activator of keratinocyte proliferation. Tildrakizumab inhibits the release of pro-inflammatory cytokines and chemokine tags.
As tildrakizumab is an IgG1 antibody, it has the potential to induce ADCC and / or CDC.
Autoimmune diseases
Moderate-severe plaque psoriasis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK